ClinicalTrials.gg
CompletedNCT03150771Updated Jun 12, 2018

Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia

A Phase 1 interventional study of Aripiprazole in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2018-06-12.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was Apr 2018, 8 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
101st of 125
36 · median 130
Started
2017
with 5 others
Phase 1
13 of 126
none open now
Registered
103rd of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 101st largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2017, is one of 13 in phase 1, and was the 103rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

This trial will determine the Pharmacokinetics, safety and tolerability of single-dose Aripiprazole administered intramuscularly in adults with schizophrenia

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female individuals between 18 and 64 years, inclusive, at screening with a current diagnosis of schizophrenia as defined by : edition 5 (DSM-5)
  • (BMI) between 18 and 35 kg/m\^2 at screening
  • Male and female subjects who are surgically sterile, female subjects who have been for at least 12 consecutive months prior to screening or male/female subjects who agree to remain abstinent or practice 2 of the approved methods from screening for at least 150 days after dose of Medical Product (IMP) for female subjects or 180 days after dose of IMP for male subjects.
  • Documented history of previously tolerating Aripiprazole per investigator's judgment.

Exclusion criteria

Exclusion Criteria:

  • Met criteria for substance use disorder within past 180 days
  • Positive drug screen for drugs of abuse
  • Use of more than 1 antipsychotic medication at screening or baseline, except for oral Aripiprazole administered during tolerability testing and current antipsychotic medication
  • Subjects may not receive varenicline beyond the screening visit.
  • Subjects who had participated in any clinical trial involving a psychotropic medication within 1 month prior to administration of IMP
  • Major surgery within 30 days prior to administration of IMP or surgery during the trial
  • Subjects at significant risk of committing suicide based on history, psychiatric exams
  • Subjects currently in an acute relapse of schizophrenia
  • Subjects with a current DSM-5 diagnosis other than schizophrenia
  • Subjects with a history of neuroleptic malignant syndrome, seizure disorder, or tardive dyskinesia
  • Subjects who have had electroconvulsive therapy within 2 months prior to administration of IMP
  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving IMP
  • History of or current hepatitis or Acquired Immunodeficiency Syndrome or carriers of surface antigen (HBsAG), antigen (anti-HCV) and/or (HIV) antibodies
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Aripiprazole; single; gluteal

    Drug: Aripiprazole

  • Experimental
    Cohort 2

    Aripiprazole; single; gluteal

    Drug: Aripiprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs) [safety and tolerability]

    AEs will be monitored to assess safety and tolerability of drug

    Time frame: Screening Days -30 to Day 182 post dose/Early Termination

  2. Clinical Laboratory Tests [safety and tolerability]

    Hematology, clinical chemistry \& urinalysis tests will be performed to assess the safety and tolerability of drug.

    Time frame: Screening Days -30 to Day 182 post dose/Early Termination

  3. Electrocardiograms (ECGs) [Safety and tolerability]

    Heart rate, RR, PR, WRS and WT intervals will be monitored to assess the safety and tolerability of the drug.

    Time frame: Screening Days -30 to Day 182 post dose/Early Termination

  4. Vital Signs [safety and tolerability]

    Systolic/diastolic blood pressure, heart rate and body temperature will be monitored to assess the safety and tolerability of the drug.

    Time frame: Screening Days -30 to Day 182 post dose/Early Termination

  5. Suicidality via Columbia-Suicide Severity Rating Scale (C-SSRS) [safety and tolerability]

    C-SSRS score will be monitored throughout the trial to assess the safety and tolerability of drug

    Time frame: Screening Days -30 to Day 182 post dose/Early Termination

  6. Extrapyramidal Symptoms (EPS) Rating Scales

    EPS score will be monitored to assess safety and tolerability of drug

    Time frame: Screening Days -30 to Day 182 post dose/Early Termination

  7. Investigator's Assessment of Injection Site

    The injection site will be monitored to assess the safety and tolerability of drug

    Time frame: Screening Days -30 to Day 182 post dose/Early Termination

  8. Visual Analog Scale (VAS) Scores for Pain Perception

    VAS score will be monitored to assess safety and tolerability of drug

    Time frame: Day 1 to Day 28 post dose

Secondary outcomes

  1. Pharmacokinetics - Maximum plasma concentration (Cmax)

    The maximum plasma concentration of drug at injection site will be assessed for plasma Aripiprazole and its major metabolite dehydro-aripiprazole

    Time frame: Day 1 to Day 182/Early Termination

  2. Pharmacokinetics - time of maximum plasma concentration (tmax)

    The amount of time that the maximum plasma concentration of drug at injection site will be assessed for plasma Aripiprazole and its major metabolite dehydro-aripiprazole

    Time frame: Day 1 to Day 182/Early Termination

  3. Pharmacokinetics - area under concentration-time curve (AUC) calculated from time zero to time t (AUCt)

    AUCt will be assessed for plasma Aripiprazole and its major metabolite dehydro-aripiprazole to determine average concentration of drug over time

    Time frame: Day 1 to Day 182/Early Termination

  4. Pharmacokinetics - AUC calculated from time to infinity

    AUCinfinity will be assessed for plasma Aripiprazole and its major metabolite dehydro-aripiprazole to determine total drug exposure over time

    Time frame: Day 1 to Day 182/Early Termination

  5. Pharmacokinetics - Terminal-phase elimination half-life (t1/2,z)

    t1/2,z will be assessed for plasma Aripiprazole and its major metabolite dehydro-aripiprazole to determine drug persistence in the body

    Time frame: Day 1 to Day 182/Early Termination

07

Study locations

3 sites
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • CNRI-San Diego
    San Diego, California 92102, United States
  • Community Clinical Research Inc.
    Austin, Texas 78754, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Apr 2018, 10 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 10 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2017
First posted
May 12, 2017
StartActual
Jun 14, 2017
Primary completionActual
Apr 18, 2018
CompletionActual
May 2, 2018
Last update
Jun 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03150771
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
May 12, 2017
Start date
Jun 14, 2017
Primary completion
Apr 18, 2018
Completion
May 2, 2018
Last update
Jun 12, 2018

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion